Hormonal Therapy and Endocrine Cancer Treatment Considerations

Hormonal Therapy and Endocrine Cancer Treatment Considerations

Hormonal (endocrine) therapy treats cancers whose growth depends on hormones or hormone receptors, most often hormone-receptor-positive breast cancer and prostate cancer. The mechanisms are: lower hormone production, block the receptor, suppress gonadal function, inhibit synthesis, or interfere with signaling. Because most regimens are taken at home for years, the RN role is education, adherence support, longitudinal symptom assessment, and escalation. This content appears in Treatment Modalities and Symptom Management OCN items.

Agent Classes and Signature Toxicities

Tamoxifen is a selective estrogen receptor modulator (SERM) that is antiestrogenic in breast tissue but proestrogenic in the uterus and clotting system, so teach reporting of leg swelling, dyspnea, and abnormal vaginal bleeding. Aromatase inhibitors block peripheral estrogen synthesis in postmenopausal patients and accelerate bone loss, so bone density monitoring and calcium/vitamin D discussion are expected.

Long-Term Adherence

A central challenge: patients feel no immediate benefit but feel daily side effects, and endocrine therapy commonly runs 5 to 10 years. Nonadherence measurably raises recurrence. Ask how many doses were missed, the time of day taken, whether cost or refill delays exist, and whether side effects disrupt sleep, work, sexuality, or mood. Use nonjudgmental language; shame suppresses honest reporting. Missed-dose direction comes from the label, pharmacist, or oncology team, never improvised by the RN.

Bone, Cardiometabolic, and Sexual Health

Estrogen and androgen suppression accelerate bone loss and fracture risk; reinforce ordered bone-density testing, weight-bearing activity, fall prevention, and dental evaluation when bone-modifying agents (denosumab, zoledronic acid) are added because of osteonecrosis-of-the-jaw risk. ADT raises weight, lipids, insulin resistance, and cardiovascular events. Sexual concerns (vaginal dryness, dyspareunia, erectile dysfunction, low libido, infertility, body-image distress) deserve assessment and referral to survivorship, fertility, sexual-health, or social-work resources.

Combination and Patient-Centered Teaching

Endocrine therapy is increasingly combined with other agents that add their own monitoring. A CDK4/6 inhibitor (palbociclib, ribociclib, abemaciclib, the -ciclib suffix) paired with an aromatase inhibitor adds neutropenia, fatigue, diarrhea, and hepatic monitoring; ribociclib specifically requires baseline and serial electrocardiograms for QT prolongation.

Teach patients that hormonal therapy is active cancer treatment, not an optional supplement, that they should keep an updated medication and supplement list, and that they should never stop therapy because of symptoms without first discussing it with the team, because many side effects are manageable with a drug holiday, switch, supportive medication, or physical therapy ordered by the provider.

Escalation

Escalate unilateral leg swelling, pleuritic chest pain, sudden dyspnea (possible deep vein thrombosis or pulmonary embolism), facial droop or one-sided weakness (stroke), severe depression or suicidal ideation, fracture symptoms, jaundice, and adrenal-insufficiency signs (hypotension, fatigue, nausea) with abiraterone, which is typically co-prescribed with prednisone precisely to prevent that crisis.

Assessing Function, Not Just Symptoms

Endocrine side effects sound minor in isolation but become treatment-limiting over years: hot flashes that wreck sleep, arthralgia that limits walking, dyspareunia that strains relationships, or low mood that erodes motivation all drive silent nonadherence. The most useful question is functional, not categorical: ask what the patient has stopped doing because of therapy. That single question reveals distress, function, and adherence risk better than a yes-or-no checklist, and it lets the nurse connect the patient with the oncology team early, before the patient quietly abandons a regimen that is reducing recurrence risk.

Pair this with survivorship planning, since these patients live with treatment effects for a long horizon.

Mechanism Detail Behind the Toxicities

Understanding mechanism explains the teaching. SERMs like tamoxifen are antiestrogenic in breast tissue but estrogen-like in the endometrium and clotting cascade, which is exactly why they raise endometrial-cancer and thromboembolism risk while still treating breast cancer; tamoxifen is also used in premenopausal patients, whereas aromatase inhibitors require a postmenopausal or ovarian-suppressed state because they cannot overcome ovarian estrogen production.

Aromatase inhibitors block the peripheral conversion of androgens to estrogen, dropping estrogen near zero and accelerating bone resorption, which drives the arthralgia and fracture risk. In prostate cancer, androgen deprivation therapy with a GnRH agonist (leuprolide) initially causes a testosterone surge, or flare, so a short course of an antiandrogen is given to prevent symptom worsening; newer agents such as enzalutamide block the androgen receptor and abiraterone blocks androgen synthesis, paired with prednisone to prevent mineralocorticoid excess and adrenal insufficiency.

Connecting each mechanism to its signature harm turns a long drug list into a predictable monitoring plan the nurse can teach and the exam can test. Fertility is a parallel priority: premenopausal patients facing ovarian suppression or years of endocrine therapy should be offered fertility counseling before treatment starts, since pregnancy is contraindicated during therapy and the window for preservation is narrow. The nurse documents that the conversation occurred and routes interested patients to reproductive-endocrinology referral early rather than after treatment begins.